Long-term use of statins may be associated with increased risks of both ductal and lobular breast cancer among women 55-74 years of age

Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age

 Authors

Abstract

Background: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use. Methods: We utilized data from a population-based case-control study of breast cancer conducted in the Seattle-Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. 916 invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases 55-74 years of age diagnosed between 2000 and 2008 were compared to 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression. Results: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14-2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25-3.12) compared to never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC [odds ratio (OR): 2.04, 95% CI: 1.17-3.57] and ILC (OR: 2.43, 95% CI: 1.40-4.21) compared to never users. Conclusion: In this contemporary population-based case-control study long-term use of statins was associated with increased risks of both IDC and ILC. Impact: Additional studies with similarly high frequencies of statin use for various durations are needed to confirm this novel finding.

  • Received April 25, 2013.
  • Revision received June 5, 2013.
  • Accepted June 6, 2013.

 

 

CEBP: Mobile Edition.

Maurice Preter, MD

About Maurice Preter MD

Maurice Preter, MD is a European and U.S. educated psychiatrist, psychotherapist, psychopharmacologist, neurologist, and medical-legal expert in private practice in Manhattan. He is also the principal of Fifth Avenue Concierge Medicine, PLLC, a medical concierge service and health advisory for select individuals and families.
This entry was posted in Aging, Complementary - Alternative Medicine, dietary, Fifth Avenue Concierge Medicine, Forensic Neuropsychiatry, Health, keto, News and tagged , . Bookmark the permalink.